Synlogic granted fast track designation from fda for labafenogene marselecobac (synb1934) for treatment of phenylketonuria

Cambridge, mass., july 11, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that the u.s. food and drug administration (fda) has granted fast track designation to labafenogene marselecobac (previously known as synb1934) for the treatment of phenylketonuria (pku). labafenogene marselecobac has also received rare disease designation (rpdd) and orphan drug designation (odd) by the fda and orphan designation from the european medicines agency (ema).
SYBX Ratings Summary
SYBX Quant Ranking